anti-Human CD19r Antibody | anti-CD19 antibody

Anti-Hu CD19 PerCP-Cy5.5

Cat. Num. AAA129289

• Gene Names: CD19; B4; CVID3
• Reactivity: Human
• Applications: Flow Cytometry, Functional Assay
• Synonyms: CD19r; N/A; Anti-Hu CD19 PerCP-Cy5.5; CD19 molecule; B4; Leu-12; CVID3; anti-CD19 antibody

• Reactivity: Human
• Isotype: Mouse IgG1
• Clone Number: LT19
• Specificity: The antibody LT19 reacts with an extracellular epitope of CD19 (B4), a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells.
• Form/Format: PerCP-Cy5.5; Purified antibody is conjugated with activated tandem dye of activated Peridinin-Chlorophyll Protein-Cyanine 5.5 (PerCP-Cy5.5) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatogr

• Applicable Applications for anti-CD19 antibody: FCM/FACS (Flow Cytometry)
• Immunogen: Daudi human Burkitt lymphoma cell line
• Preparation and Storage: Store at 2-8 degree C. Protect from prolonged exposure to light. Do not freeze.

FCM/FACS (Flow Cytometry)

(Separation of human CD19 positive lymphocytes (red-filled) from CD19 negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD19 (LT19) PerCP-Cy™5.5 antibody (4 ?l reagent / 100 ?l of peripheral whole blood).)

FCM/FACS (Flow Cytometry)

(Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD19 (LT19) PerCP-Cy™5.5 antibody (4 ?l reagent / 100 ?l of peripheral whole blood).)

Related Product Information for anti-CD19 antibody

CD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.

References

*Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005 Nov 15;106(10):3567-74. Epub 2005 Jul 26., URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16046525&query_hl=14&itool=pubmed_DocSum,*Stehlíková O, Chovancová J, Tichý B, Krej?í M, Brychtová Y, Panovská A, Francová Skuhrová H, Bur?ková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol. 2013 Sep 13. doi: 10.1111/ijlh.12149., URL: http://www.ncbi.nlm.nih.gov/pubmed/24028768,*Kayserova J, Vcelakova J, Stechova K, Dudkova E, Hromadkova H, Sumnik Z, Kolouskova S, Spisek R, Sediva A: Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients. Clin Immunol. 2014 Jul;153(1):49-55., URL: http://www.ncbi.nlm.nih.gov/pubmed/24709112,*Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 2003 Oct 1;171(7):3697-704., URL: https://www.ncbi.nlm.nih.gov/pubmed/14500668?dopt=,*Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, Tree T, Leslie RD, Tremble JM, Dayan CM, Peakman M: Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes. 2009 Jan;58(1):138-45., URL: https://pubmed.ncbi.nlm.nih.gov/18835928/,
*Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 2007 Sep;56(9):3057-69., URL: https://pubmed.ncbi.nlm.nih.gov/17763445/,*van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006 May 4;354(18):1901-12., URL: https://pubmed.ncbi.nlm.nih.gov/16672701/,*Inabe K, Kurosaki T: Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 15;99(2):584-9., URL: https://pubmed.ncbi.nlm.nih.gov/11781242/,*Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol. 1999 Jun 15;162(12):7088-94., URL: https://pubmed.ncbi.nlm.nih.gov/10358152/,

NCBI and Uniprot Product Information

• NCBI GI #: 296010921
• NCBI GeneID: 930
• NCBI Accession #: NP_001171569.1
• NCBI GenBank Nucleotide #: NM_001178098.1
• UniProt Accession #: P15391; Q96S68; Q9BRD6; A0N0P9
• Molecular Weight: 61,128 Da
• NCBI Official Full Name: B-lymphocyte antigen CD19 isoform 1
• NCBI Official Synonym Full Names: CD19 molecule
• NCBI Official Symbol: CD19
• NCBI Official Synonym Symbols: B4; CVID3
• NCBI Protein Information: B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
• UniProt Protein Name: B-lymphocyte antigen CD19
• UniProt Gene Name: CD19
• UniProt Entry Name: CD19_HUMAN